AU6290998A - 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use - Google Patents

4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use

Info

Publication number
AU6290998A
AU6290998A AU62909/98A AU6290998A AU6290998A AU 6290998 A AU6290998 A AU 6290998A AU 62909/98 A AU62909/98 A AU 62909/98A AU 6290998 A AU6290998 A AU 6290998A AU 6290998 A AU6290998 A AU 6290998A
Authority
AU
Australia
Prior art keywords
thieno
tetrahydro
preparation
pyridine derivatives
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62909/98A
Other languages
English (en)
Inventor
Helle Demuth
Morten Heide
Jane Marie Lundbeck
Peter Madsen
Lars Naerum
Annemarie Reinhardt Varming
Niels Westergaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU6290998A publication Critical patent/AU6290998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU62909/98A 1997-03-07 1998-03-06 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use Abandoned AU6290998A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK249/97 1997-03-07
DK24997 1997-03-07
DK1365/97 1997-11-27
DK136597 1997-11-27
PCT/DK1998/000083 WO1998040385A1 (fr) 1997-03-07 1998-03-06 DERIVES DE 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE, LEUR PREPARATION ET LEUR UTILISATION

Publications (1)

Publication Number Publication Date
AU6290998A true AU6290998A (en) 1998-09-29

Family

ID=26063610

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62909/98A Abandoned AU6290998A (en) 1997-03-07 1998-03-06 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use

Country Status (4)

Country Link
EP (1) EP0973778A1 (fr)
JP (1) JP2001514631A (fr)
AU (1) AU6290998A (fr)
WO (1) WO1998040385A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2610499A (en) * 1998-03-06 1999-09-20 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno(3,2-c)pyridine derivatives
US6090797A (en) * 1998-09-02 2000-07-18 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno(2,3-C)pyridine derivatives
WO2000014090A1 (fr) * 1998-09-02 2000-03-16 Novo Nordisk A/S Derives de 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine
US8481268B2 (en) 1999-05-21 2013-07-09 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8080380B2 (en) 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
ATE346613T1 (de) 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
JP2005522408A (ja) 2001-07-13 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−ＨＴ受容体リガントとしてのヘキサヒドロアゼピノ（４，５−ｇ）インドールおよびインドリン
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CA2512546A1 (fr) * 2003-01-17 2004-08-05 Merck & Co., Inc. Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
CN101792417A (zh) 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
MXPA05013364A (es) 2003-06-17 2006-03-17 Arena Pharm Inc Procedimiento para preparar 3-benzazepinas.
CN100516041C (zh) * 2003-07-15 2009-07-22 大日本住友制药株式会社 新型杂芳基衍生物
JP5069907B2 (ja) 2003-09-17 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 縮合複素環式化合物
SI1838677T1 (sl) 2004-12-21 2010-01-29 Arena Pharm Inc Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
TWI378090B (en) 2005-04-13 2012-12-01 Astex Therapeutics Ltd Pharmaceutical compounds
MY159522A (en) 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
SG10201508066VA (en) 2006-04-03 2015-10-29 Arena Pharm Inc Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073807A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
WO2008044027A2 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Composés pharmaceutiques
ES2522587T3 (es) 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
CL2008003749A1 (es) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
WO2009111004A1 (fr) 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Procédés de préparation d'intermédiaires se rapportant à l'agoniste 5-ht<sb>2c</sb> (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazepine
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
EP2443080A2 (fr) 2009-06-18 2012-04-25 Arena Pharmaceuticals, Inc. Procédés pour la préparation d'agonistes du récepteur 5-ht<sb>2c</sb>
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011153206A1 (fr) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Procédés pour la préparation d'agonistes du récepteur 5-ht2c
CN101863900B (zh) * 2010-06-29 2012-07-25 天津药物研究院 一氧化氮供体型噻吩并吡啶衍生物、其制备方法和用途
SG188365A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
EP2611433A2 (fr) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Sels non hygroscopiques d'agonistes de 5-ht2c
EP2611782A1 (fr) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Sels de lorcasérine dotés d'acides optiquement actifs
AU2013235487B2 (en) * 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
KR20190128001A (ko) 2012-10-09 2019-11-13 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리 방법
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
EP3331876B1 (fr) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulateurs de ror-gamma
MX2018006223A (es) 2015-11-20 2018-12-19 Vitae Pharmaceuticals Inc Moduladores de ror-gamma.
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2017218874A1 (fr) * 2016-06-16 2017-12-21 Memorial Sloan-Kettering Cancer Center Inhibiteurs d'acyltransférase hedgehog et utilisations de ces derniers
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
EP3658555A1 (fr) 2017-07-24 2020-06-03 Vitae Pharmaceuticals, LLC Inhibiteurs de ror
CU20200037A7 (es) 2017-11-02 2021-03-11 Aicuris Gmbh & Co Kg Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb)
EP3941905A1 (fr) * 2019-03-19 2022-01-26 Suvalent Therapeutics, Inc. Composés inhibiteurs de sumo et leurs utilisations
WO2023137297A2 (fr) * 2022-01-11 2023-07-20 Suvalent Therapeutics, Inc. Inhibiteurs de 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo et leurs utilisations
CN114507155A (zh) * 2022-02-16 2022-05-17 浙江欣禾生物股份有限公司 一种间三氟甲基苯乙酮肟的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD210278A5 (de) * 1982-03-05 1984-06-06 Boehringer Ingelheim Kg Verfahren zur herstellung neuer basisch substituierter 4-phenyl-4,5,6,7-tetrahydro-thieno-(2,3-c)pyridine
DE3412947A1 (de) * 1984-04-06 1985-10-17 Bayer Ag, 5090 Leverkusen Tetrahydothienopyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB8429087D0 (en) * 1984-11-16 1984-12-27 Scras Thienopyridine derivatives
FR2595356B1 (fr) * 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
FR2733750B1 (fr) * 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP0973778A1 (fr) 2000-01-26
JP2001514631A (ja) 2001-09-11
WO1998040385A1 (fr) 1998-09-17

Similar Documents

Publication Publication Date Title
AU6290998A (en) 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
IL119565A0 (en) Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e] indol-8-ones derivatives thereof and their use
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
IL118380A0 (en) Substituted pyridine derivatives their preparation and use
IL132967A0 (en) 3-Substituted 3,4-dihydro-thieno¬2,3-d¾pyrimidine derivatives and production and use of the same
PL332144A1 (en) Derivatives of pyrido-[4&#39;,3&#39;:4,5]thiene[2,3-d]-pyrimidine substituted at position 3, their production and application
AU4559497A (en) 1H-pyrido{3,4-b}indole-4-carboxamide derivatives, their preparation and their application in therapeutics
PL332382A1 (en) Derivatives of 1,2,3,4-tetrahydro-benzofuro [3,2-c] pyridine
IL131645A (en) Pyrimido ¬1,2-a¾indole derivatives and their preparation
ZA9725B (en) 4,5-Dihydronaphth[1,2-c]isoxazoles and derivatives thereof
EG21121A (en) 13 Substituted milbemycin derivatives their preparation and use
AU5154699A (en) 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
AU3693797A (en) 1,3-dimethyl-5-fluoro-pyrazole-4-carboxamide derivatives, their preparation and their use as microbicides
AU2406597A (en) Thienopyridine derivatives, their production and use
AU2030197A (en) 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof
AU2405397A (en) Thienopyridine derivatives and their use
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
IL132985A0 (en) 3-Substituted pyrido ¬3&#39;4&#39;:4,5¾thieno ¬2,3-d¾pyrimidine derivatives and production and use of the same
GB2324090B (en) 5,6-O-alkylidene glucono-1(4)-lactones and derivatives thereof,their preparation and use
HUP0002659A3 (en) Benzo-5,6-cyclohepta[1,2-b]pyridine derivatives, pharmaceutical compositions containing them and their use
ZA981965B (en) 4,5,6,7-tetrahydro-thieno(3,2-C)pyridine derivatives their preparation and use
ZA953749B (en) 5,6-dihydro-4H-thieno[3,4-c] pyrroie derivatives their preparation and their therapeutic application
ZA9811642B (en) Pyrido 1,2,4-thiadiazine derivatives their preparation and use
AU3147500A (en) Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use